| 标题 |
Abstract 1260: First-in-class, orally bioavailable KRASG12V(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers |
| 网址 | |
| DOI | |
| 其它 |
期刊:Cancer Research 作者:Elena Koltun; Jim Cregg; Meghan A. Rice; Dan M. Whalen; Rebecca Freilich; et al 出版日期:2021-07-01 |
| 求助人 | |
| 下载 | 求助已完成,仅限求助人下载。 |
PDF的下载单位、IP信息已删除
(2025-6-4)